{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:54:41Z","timestamp":1775210081938,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Current therapy for Anderson\u2013Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the comfort of their own homes. The 2020\u20132021 COVID-19 pandemic has pushed global healthcare providers to evolve their services so as to minimize the risk of COVID-19 exposure to both patients and providers; this has led to advances in telemedicine services and the increasing availability of at-home treatment for various procedures including parenteral drug administration. A total of 80% of surveyed Anderson\u2013Fabry disease patients in Poland would prefer home-based treatment, which would be a safe and convenient alternative to clinic-based treatment if patient selection is based on our proposed algorithm. Our recommendations for home-based treatments appear feasible for the long term care of Anderson\u2013Fabry disease patients during the COVID-19 pandemic and beyond. This may also serve as a basis for home-based treatment programs in other rare and ultra-rare genetic diseases.<\/jats:p>","DOI":"10.3390\/ijerph18168242","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T08:47:52Z","timestamp":1628066872000},"page":"8242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-5440","authenticated-orcid":false,"given":"Micha\u0142","family":"Nowicki","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension, and Kidney Transplantation, Medical University of \u0141\u00f3d\u017a, 90-145 \u0141\u00f3d\u017a, \u0141\u00f3dzkie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-0963","authenticated-orcid":false,"given":"Stanis\u0142awa","family":"Bazan-Socha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Krak\u00f3w, Ma\u0142opolskie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"K\u0142opotowski","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology and Angiology, Institute of Cardiology, 04-628 Warsaw, Mazowieckie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"B\u0142a\u017cejewska-Hy\u017corek","sequence":"additional","affiliation":[{"name":"2nd Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Mazowieckie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6502-0374","authenticated-orcid":false,"given":"Mariusz","family":"Kusztal","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation Medicine, Wroc\u0142aw Medical University, 50-556 Wroc\u0142aw, Dolno\u015bl\u0105skie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6237-0814","authenticated-orcid":false,"given":"Krzysztof","family":"Pawlaczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital of Karol Marcinkowski in Zielona G\u00f3ra, 65-046 Zielona G\u00f3ra, Lubuskie, Poland"},{"name":"Department of Nephrology, Transplantology, and Internal Diseases, Pozna\u0144 University of Medical Sciences, 60-355 Pozna\u0144, Wielkopolskie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"S\u0142awek","sequence":"additional","affiliation":[{"name":"Division of Neurological and Psychiatric Nursing, Institute of Nursing and Midwifery, Medical University of Gda\u0144sk, 80-462 Gda\u0144sk, Pomorskie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3394-7140","authenticated-orcid":false,"given":"Andrzej","family":"Oko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology, and Internal Diseases, Pozna\u0144 University of Medical Sciences, 60-355 Pozna\u0144, Wielkopolskie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-1630","authenticated-orcid":false,"given":"Zofia","family":"Oko-Sarnowska","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pozna\u0144 University of Medical Sciences, 60-355 Pozna\u0144, Wielkopolskie, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e12914","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"Reisin","year":"2017","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1056\/NEJMp2003539","article-title":"Virtually perfect? Telemedicine for Covid-19","volume":"382","author":"Hollander","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jadohealth.2020.05.024","article-title":"Telemedicine in the time of COVID and beyond","volume":"67","author":"North","year":"2020","journal-title":"J. Adolesc. Health"},{"key":"ref_5","first-page":"91","article-title":"Enzyme replacement therapy in Fabry disease in Poland: A position statement","volume":"130","author":"Nowicki","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_6","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2021, July 02). Monitoring and follow-up of patients, Fabry Disease: Perspectives from 5 Years of FOS [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11569\/."},{"key":"ref_7","first-page":"85","article-title":"Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group","volume":"12","author":"Concolino","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2020.07.008","article-title":"Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience","volume":"131","author":"Riccio","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: Practice guidelines based on 3 years\u2019 experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","first-page":"2345","article-title":"Home-based infusion therapy\u2014A feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry\u2019s disease","volume":"138","author":"Beck","year":"2013","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_11","unstructured":"(2021, July 02). Sytuacja Chorych Na Chorob\u0119 FABRY\u2019EGO w Polsce. Available online: https:\/\/www.pexps.pl\/files\/upload\/files\/PEX_SytuacjaChorychFabry_20180615.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.17219\/acem\/132038","article-title":"Is home-based therapy in Fabry disease the answer to compelling patients\u2019 needs during the COVID-19 pandemic? Survey results from the Polish FD Collaborative Group","volume":"30","author":"Kusztal","year":"2021","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A revised home treatment algorithm for Fabry disease: Influence of antibody formation","volume":"108","author":"Smid","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2362.2010.02363.x","article-title":"Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion","volume":"40","author":"Guest","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ymgme.2019.11.236","article-title":"Home infusion therapy with agalsidase alfa for patients with Fabry disease in Germany and Austria","volume":"129","author":"Lachmann","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_17","first-page":"31","article-title":"Home infusion program for Fabry disease: Experience with agalsidase alfa in Argentina","volume":"73","author":"Kisinovsky","year":"2013","journal-title":"Medicina (B Aires)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2020.04.002","article-title":"Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience","volume":"130","author":"Sechi","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_19","unstructured":"Fraser, N., Georgiou, P., Brown, M., Bischoff, C., and Agnew, R. (2014, January 2\u20135). The Australian ATHOMETM Infusion service experience. Proceedings of the Society for the Study of Inborn Errors of Metabolism (SSIEM), 2014 Annual Symposium, Innsbruck, Austria."},{"key":"ref_20","unstructured":"(2021, July 01). Fabry Outcome Survey Annual Report 2016. Available online: http:\/\/sffd.ch\/wp-content\/uploads\/2017\/12\/FOS-Patient-Report-2016-Final.pdf."},{"key":"ref_21","unstructured":"(2021, July 01). V Dob\u011b Pandemie Onemocn\u011bn\u00ed Covid-19 Jsou Pacienti Se Vz\u00e1cn\u00fdmi Onemocn\u011bn\u00edmi Vysoce Rizikovou Skupinou. Available online: http:\/\/www.vzacna-onemocneni.cz\/images\/dokumenty\/Odborne_clanky\/koronavirus\/Koronavirus_-_stanovisko_CAVO_final.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","article-title":"Home-based infusion therapy for patients with Fabry disease","volume":"11","author":"Cousins","year":"2008","journal-title":"Br. J. Nurs."},{"key":"ref_23","unstructured":"Casa Na\u0163ional\u0103 de Asigur\u0103ri de S\u0103n\u0103tate (2021, July 01). Available online: http:\/\/www.cnas.ro\/post\/type\/local\/comunicat-medicii-curanti-vor-decide-cazurile-pentru-care-se-continua-tratamentele-i-investigatiile.html."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2020.06.002","article-title":"Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued","volume":"130","author":"Politei","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","unstructured":"Health Resources & Services Administration (2020, July 01). Telehealth Programs [Internet], Available online: https:\/\/www.hrsa.gov\/rural-health\/telehealth\/index.html."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/1460458215592042","article-title":"Towards a shared service centre for telemedicine: Telemedicine in Denmark, and a possible way forward","volume":"22","author":"Larsen","year":"2016","journal-title":"Health Inform. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.2196\/jmir.6688","article-title":"Telehealth interventions to support self-management of long-term conditions: A systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer","volume":"19","author":"Hanlon","year":"2017","journal-title":"J. Med. Internet Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13364","article-title":"Use of telehealth in the delivery of comprehensive care for patients with haemophilia and other inherited bleeding disorders","volume":"24","author":"Kulkarni","year":"2018","journal-title":"Haemophilia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2020.3972","article-title":"Supporting the health care workforce during the COVID-19 global epidemic","volume":"323","author":"Adams","year":"2020","journal-title":"JAMA"},{"key":"ref_30","unstructured":"(2021, July 01). Homecare Provider: Bridging the Gap between Community and Hospital Pharmacy. Available online: https:\/\/pharmaceutical-journal.com\/article\/news\/homecare-provider-bridging-the-gap-between-community-and-hospital-pharmacy."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014A comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/8904_2011_106","article-title":"Severe infusion reactions to Fabry enzyme replacement therapy: Rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"141","author":"Lenders","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rombach, S.M., Aerts, J.M.F.G., Poorthuis, B.J.H.M., Groener, J.E.M., Donker-Koopman, W., Hendriks, E., Mirzaian, M., Kuiper, S., Wijburg, F.A., and Hollak, C.E.M. (2012). Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047805"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","article-title":"Home treatment with intravenous enzyme replacement therapy for Gaucher disease: An international collaborative study of 33 patients","volume":"82","author":"Zimran","year":"1993","journal-title":"Blood"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/16\/8242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:10Z","timestamp":1760164810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/16\/8242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":45,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijerph18168242"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18168242","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}